For people hoping that Big Pharma Could still be barred from the medical-marijuana scene there is bad news: the agreement is done. Keep your eyes open for the first naturally derived, Big Pharma develops marijuana products to be released to the public to purchase the frosted half of 2016, perhaps even sooner.
Epidiolex is a liquid formulation of pure, plant derived cannabidiol, developed by the British company, G.W. Pharmaceuticals. It is as now on the FDA Fast Track ad has entered its last Phase 3 testing for pediatric epilepsy disorders such as Dravet’s and Lennox-Gastaut’s syndromes with results scheduled for the first quarter of 2016.
Dealing with an unlikely catastrophic discovery, there are many indicators that Epidiolex will breeze through this last stage and will thus have hurdled the FDA’s testing standards. For various different drugs, the remaining details would be purely administrative yet Epidiolex is derived from marijuana and that puts a few more obstacles in the way before marketing can start. There are, however, a good amount of signs that government officials are currently making a way for this new player.
Among the most crucial happened on June 24, 2015. Prior to a full hearing room, the U.S. Senate Caucus on International Narcotics Control, starting back from 1985 to “expand international cooperation against drug abuse and narcotics trafficking” took on the decidedly domestic problem of what to do about medical marijuana. The conference was chaired by two unlikely medical marijuana supporters, Senators Charles Grassley and Dianne Feinstein.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
1 comment
Unfortunately for the average grower as well as the small company selling seeds, products and dispensary items such as cannabis, the legal issue is merely a test case. The state(s) as well as the Federal government have implemented a clause when (not if) full legalization comes to pass. But there will be strict guidelines, imposed and derived through corporate (big pharm) and the regulatory bodies in DC. The test case is seeing the numbers and knowing that cannabis is becoming more or less mainstream. The regular, media-fed public isn’t about to walk into a corner dispensary anytime soon, yet only when the state gives the go-ahead will they freely be able to have a choice; and the choice is the big pharmaceutical brands that will be the only thing on the shelves. Legalization is set up this way and once all the rhetoric and protesting fades away, it will become the norm.
The failures will be choice and independence.